Ida Orfin
Vice President, Investor Relations
Replay available
Levi Strauss & Co. (NYSE: LEVI) Q4 2025 earnings conference call, held 2026-01-28. Replay captured from the company's public earnings webcast.

Vice President, Investor Relations
President and CEO
Chief Financial and Growth Officer
Analyst, BNP Paribas
Analyst, JPMorgan
Analyst, UBS
Analyst, BCIG
Analyst, TV Cohen
Watch the replay and follow the connected company analysis, news, and investor updates for Levi Strauss & Co.
WEBVTT 00:00:00.031 -- 00:00:04.036 Good day, ladies and gentlemen, and welcome to the Levi Strauss & Company fourth quarter 00:00:04.036 -- 00:00:09.262 fiscal year-end earnings conference call for the period ending November 30th, 00:00:09.262 -- 00:00:11.104 2025. 00:00:11.104 -- 00:00:15.690 All parties will be in a listen-only mode until the question and answer session, at which 00:00:15.690 -- 00:00:18.833 time instructions will follow. 00:00:18.833 -- 00:00:22.958 This conference call is being recorded and may not be reproduced in whole or in part 00:00:22.958 -- 00:00:26.062 without written permission from the company. 00:00:26.062 -- 00:00:28.702 This conference call is being broadcast over the internet. 00:00:28.702 -- 00:00:34.248 and a replay of the webcast will be accessible for one quarter on the company's website, 00:00:34.248 -- 00:00:36.248 LeviStrauss.com. 00:00:36.790 -- 00:00:41.635 I would now like to turn the call over to Ida Orfin, Vice President of Investor Relations 00:00:41.635 -- 00:00:43.777 at Levi Strauss & Company. 00:00:43.777 -- 00:00:47.641 Thank you for joining us on the call today to discuss the results for our fourth quarter 00:00:47.641 -- 00:00:51.685 and fiscal year-end. Joining me on today's call are Michelle Goss, our President and 00:00:51.685 -- 00:00:55.415 CEO, and Harmeet Singh, our Chief Financial and Growth Officer. 00:00:55.415 -- 00:00:59.159 We'd like to remind you that we will be making forward-looking statements based on current 00:00:59.159 -- 00:01:03.324 expectations, and those statements are subject to certain risks and uncertainties that 00:01:03.324 -- 00:01:06.167 could cause actual results to differ materially. 00:01:06.167 -- 00:01:10.351 These risks and uncertainties are detailed in our reports filed with...